ViiV's Dovato Could Challenge Status Quo In Naive EU HIV Patients

The approval of ViiV’s new once-daily, two-drug single-pill for HIV/AIDS could lead to a tough battle in Europe with established therapies.   

Mountain
Reaching the top spot in HIV/AIDS therapies will likely be a tough climb. • Source: Shutterstock

Two months after gaining US approval, ViiV Healthcare  has received an EU marketing authorization for its new once-daily single-pill two-drug HIV combination, Dovato (dolutegravir 50mg/lamivudine 300mg) tablets, a potential blockbuster product which could challenge market leaders, including Gilead Sciences Inc.'s Biktarvy (bictegravir 50mg/emtricitabine 200mg/tenofovir alafenamide fumarate 25mg) tablets, in the sector.

ViiV highlighted the potential role of Dovato as first-line therapy for treatment-naive patients in its approval announcement on 3 July:...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from New Products

More from Scrip